Reply
First we thank Frederick Wolfe for seriously reading and criticizing our article from the outside of Plato's cave [1] . Secondly, after reading his comment, it seems we have to make our statement more clear. Wolfe states that we said fibromyalgia does not exist and that we should give some proof for this statement (or rather: we should give proof, like he does, that fibromyalgia really does not exist). However, neither in the quote of Wolfe in our article ('Wolfe's assertion that fibromyalgia will always be with us [. . .] regardless of what name the syndrome has, is unlikely to be true'), nor elsewhere in our article, do we say that fibromyalgia does not exist. There are specific people complaining of pain, sleeping disorders and fatigue who have been 'diagnosed' as fibromyalgia patients. We are neither denying the existence of these patients nor their complaints.
So, we also know that fibromyalgia exists, but not in the same way an object in Plato's world of ideas is supposed to exist outside the cave. The form of representation called fibromyalgia must not be confused with a shadow of a Platonic idea. There is no such objective thing as fibromyalgia, in contrast to measurable inflammation factors or any other organic disease. What clinicians, by using classification criteria (although often called diagnostic criteria), recognize as fibromyalgia is a way of behaviour, a phenomenon, a representation of complaints changing in time. By applying 'diagnostic' criteria to a data bank Wolfe tries to prove the existence of fibromyalgia. But isn't that similar to how we know fibromyalgia exists (and even in a way is produced)?
The proof of the existence of fibromyalgia is the proof of relationships in a therapeutic domain and the processes of assigning meaning. By only looking backwards and applying criteria on already ill diagnosed and classified people in a huge data bank, it is not possible to find the proof of the existence of certain processes and relationships. That is Whig history: explaining the past from the knowledge of the present.
In a prospective field study in a society in which the diagnosis of fibromyalgia does not exist, we may study which people will be going to complain of fatigue, pain and different somatic symptoms in the future. In such a setting we may be able to study the processes and relationships that lead to the diagnosis of a syndrome like fibromyalgia. We may also be able to study how to prevent the diagnosis from being made.
Wolfe stated he has tried to give us some proof of the existence of fibromyalgia from the outside of Plato's cave. First, by applying the criteria he stood in the middle of the cave. Second, do we still remember that there was supposed to be a supernatural world outside Plato's cave? In reply to Wolfe Ischaemic heart disease in rheumatoid arthritis patients SIR, We read with an interest the recent editorial by Kitas and Erb [1] . Patients with rheumatoid arthritis (RA) have a reduced life expectancy when compared with the general population. Recent studies showed that cardiovascular death is considered to be the leading cause of mortality in patients with RA [2] . It is thought to be due to accelerated atherosclerosis via persistent inflammation. Wallberg-Jonsson et al. [3] examined cardiovascular morbidity and mortality in a cohort of seropositive RA patients. They found that 34% of their cohort had a cardiovascular event during 15 yr of follow-up. Del Rincon et al. [4] showed that the incidence of cardiovascular events in RA was 3.43/100 patient-years vs 0.59/100 patient-years in controls. Risk factors for cardiovascular events are not properly addressed in our busy rheumatology outpatient clinics. So we did a small study to check traditional cardiovascular risk factors in RA patients in out-patient clinics. We recruited 98 successive patients from our rheumatology outpatient clinics. We gave particular importance to the fasting lipid profile and body mass index. Twelve out of 98 patients (12.24%) had a personal history of ischaemic heart disease (IHD). Most of the patients were taking aspirin and anti-anginal medications. The lipid profile was analysed in the fasting blood sample. The mean cholesterol level was 5.3 mmol in patients with a history of IHD and 5.6 mmol in other patients. Forty-nine patients had a mean cholesterol/high-density lipoprotein (HDL) ratio of more than 4.44 mmol (upper limit of normal is 4.44 mmol), including five patients with IHD. Thirty-five patients with a cholesterol/HDL ratio of more than 4.44 were not taking statins, including two patients with a history of IHD. It is interesting to note that the mean body mass index (BMI) was 27.96, and 56 patients had a BMI of more than 25. Lipids and hypertension may relate to obesity and a sedentary lifestyle. These factors are now considered as major ischaemic risk factors.
Significant proportions of our patients with a high cholesterol/ HDL ratio were not taking statins, and these included five patients with IHD. More than 50% of patients had a high BMI (>25). It is debatable whether we should counsel all RA patients regarding cardiovascular risk factors and check their fasting lipids and glucose. It may be impossible to assess the risk factors in busy rheumatological out-patient clinics, but we could advise general practitioners to do this. There are no data available suggesting the threshold value for treating dyslipidaemia in RA patients. While hypertension and diabetes are commonly identified and treated, dyslipidaemia is frequently forgotten as an important risk factor. So the question unanswered is whether we should have a lower threshold for treating dyslipidaemia in RA patients.
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Correspondence to: S. Saravana. E-mail: adersh555saravana@ hotmail.com In a similar study of CVD risk factors in rheumatology out-patients, we found even higher levels of comorbid CVD than that detected by Saravana et al. (total cardiovascular comorbidity 34%; angina 16%, previous myocardial infarct 8%, cerebrovascular accident 4%, peripheral vascular disease 2%, treatment for hypertension 28%, and treatment for hypercholesterolaemia 4%). Of more concern is that in the remaining RA patients with no known CVD we also found a high prevalence of hypertension (systolic blood pressure >140 mmHg in 56.4%), hypercholesterolaemia (total cholesterol >5 mmol/l in 71.3%) and obesity (mean body mass index 27.6 kg/m 2 ). Also, 22.3% were current smokers and 5.3% had diabetes mellitus [1] . These results are similar to those of other groups in the UK [2] and the USA [3] .
We entirely agree with Saravana et al. that lipids and obesity are important factors in the development of CVD, but we believe that they should not be viewed or managed in isolation. We would advocate using a composite scoring system for the calculation of CVD risk to prevent undue emphasis being placed on any one risk factor to the detriment of others. There are several risk calculators based on the original Framingham data and modified over the ensuing years, as more accurate risk prediction models have been developed. In our clinics we use the Joint Societies Risk calculator [4] , which is widely available at the back of the British National Formulary books and as an on-line version, and is rapid and easy to use in the clinical setting.
We recognize that implementing CVD risk assessment in busy rheumatology out-patient departments is difficult. However, we feel that at present this is by far the most appropriate setting. Even though evidence for increased cardiovascular mortality in RA has been around for a long time, awareness of it has started to become widespread amongst the rheumatological community only recently. It is likely (indeed this has been our experience locally) that awareness of this problem in primary care will lag even further behind. Once CVD risk assessment in RA is established in secondary care, and some peculiarities of it in the RA population have been sorted out through further research (e.g. the significance and interpretation of lipid levels during active inflammation), education and support for primary care physicians in undertaking this activity will be easier. Symptom concealment-a new phenomenon in patients treated with biological therapies? SIR, The articles and discussion by Kroesen et al. [1] and Moots et al. [2] on the association of 'infection in general' with biological therapies raise many important issues for clinical rheumatologists. At St George's NHS Trust we have treated 60 patients with infliximab, etanercept or adalimumab since 1999. Two patients have been admitted with severe infections, one with Haemophilus influenzae empyema and another with Pseudomonas pneumonia. Both patients were smokers but had had no previous history of symptomatic pulmonary disease or of significant chest sepsis. In both cases a delay of several weeks occurred between the onset of symptoms and admission to hospital. Part of this delay included a period of blind treatment by the general practitioner with antibiotics, without reference to the rheumatology department. However, in both cases a significant period of delay also occurred before the patient consulted the general practitioner, despite repeated warnings from our department to seek medical advice promptly should infective symptoms occur. We have ascertained that in these cases the patients consciously delayed seeking medical help, against advice, because they feared that this would lead to
